{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:47:43Z","timestamp":1777603663343,"version":"3.51.4"},"reference-count":100,"publisher":"Elsevier","isbn-type":[{"value":"9780128151112","type":"print"}],"license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018]]},"DOI":"10.1016\/bs.enz.2018.08.004","type":"book-chapter","created":{"date-parts":[[2018,10,5]],"date-time":"2018-10-05T19:02:10Z","timestamp":1538766130000},"page":"83-101","source":"Crossref","is-referenced-by-count":27,"title":["Nanoparticle Delivery of TWIST Small Interfering RNA and Anticancer Drugs: A Therapeutic Approach for Combating Cancer"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.enz.2018.08.004_bb0010","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","article-title":"Advances in ovarian cancer therapy","volume":"81","author":"Cortez","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0015","first-page":"159","article-title":"Interaction between tumor and immune system: the role of tumor cell biology","volume":"32","author":"Berezhnaya","year":"2010","journal-title":"Exp. Oncol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0020","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1517\/14728214.2015.1036739","article-title":"Emerging therapies: angiogenesis inhibitors for ovarian cancer","volume":"20","author":"Jackson","year":"2015","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"10.1016\/bs.enz.2018.08.004_bb0025","first-page":"580","article-title":"Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?","volume":"20","author":"Solmaz","year":"2015","journal-title":"J. BUON"},{"issue":"10","key":"10.1016\/bs.enz.2018.08.004_bb0030","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3390\/ijms18102171","article-title":"Emerging therapeutics to overcome chemoresistance in epithelial ovarian cancer: a mini-review","volume":"18","author":"Cornelison","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.enz.2018.08.004_bb0035","doi-asserted-by":"crossref","first-page":"55771","DOI":"10.18632\/oncotarget.9908","article-title":"Targeting epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer","volume":"7","author":"Deng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/bs.enz.2018.08.004_bb0040","first-page":"52","article-title":"Breast cancer statistics, 2013","volume":"64","author":"DeSantis","year":"2014","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/bs.enz.2018.08.004_bb0045","first-page":"10","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/bs.enz.2018.08.004_bb0050","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1080\/02841860500513235","article-title":"Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors","volume":"45","author":"Al Sayed","year":"2006","journal-title":"Acta Oncol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0055","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jinorgbio.2006.09.022","article-title":"Antiproliferative activity of Pt(II) and Pd(II) phosphine complexes with thymine and thymidine","volume":"101","author":"Messere","year":"2007","journal-title":"J. Inorg. Biochem."},{"key":"10.1016\/bs.enz.2018.08.004_bb0060","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1593\/neo.91084","article-title":"Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression","volume":"11","author":"Vesuna","year":"2009","journal-title":"Neoplasia"},{"key":"10.1016\/bs.enz.2018.08.004_bb0065","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbrc.2007.11.151","article-title":"Twist is a transcriptional repressor of E-cadherin gene expression in breast cancer","volume":"367","author":"Vesuna","year":"2008","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.enz.2018.08.004_bb0070","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s10911-009-9110-3","article-title":"The epithelial-to-mesenchymal transition and cancer stem cells: a coalition against cancer therapies","volume":"14","author":"Hollier","year":"2009","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"key":"10.1016\/bs.enz.2018.08.004_bb0075","doi-asserted-by":"crossref","first-page":"716","DOI":"10.3390\/cancers30100716","article-title":"Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins?","volume":"3","author":"Kong","year":"2011","journal-title":"Cancers (Basel)"},{"key":"10.1016\/bs.enz.2018.08.004_bb0080","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/bcr2876","article-title":"Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition","volume":"13","author":"Takebe","year":"2011","journal-title":"Breast Cancer Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0085","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.ccr.2008.06.005","article-title":"Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence","volume":"14","author":"Ansieau","year":"2008","journal-title":"Cancer Cell"},{"key":"10.1016\/bs.enz.2018.08.004_bb0090","first-page":"3851","article-title":"Expression of twist and wnt in human breast cancer","volume":"24","author":"Watanabe","year":"2004","journal-title":"Anticancer Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0095","doi-asserted-by":"crossref","first-page":"R719","DOI":"10.1016\/j.cub.2004.08.048","article-title":"Tumor metastasis: a new twist on epithelial-mesenchymal transitions","volume":"14","author":"Vernon","year":"2004","journal-title":"Curr. Biol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0100","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s10585-009-9291-6","article-title":"Metastasis-induction and apoptosis-protection by TWIST in gastric cancer cells","volume":"26","author":"Feng","year":"2009","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/bs.enz.2018.08.004_bb0105","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1101\/gad.13.17.2207","article-title":"Twist is a potential oncogene that inhibits apoptosis","volume":"13","author":"Maestro","year":"1999","journal-title":"Genes Dev."},{"key":"10.1016\/bs.enz.2018.08.004_bb0110","doi-asserted-by":"crossref","first-page":"522","DOI":"10.7150\/ijbs.4164","article-title":"TWIST represses estrogen receptor-alpha expression by recruiting the NuRD protein complex in breast cancer cells","volume":"8","author":"Fu","year":"2012","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/bs.enz.2018.08.004_bb0115","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1038\/onc.2011.483","article-title":"Twist contributes to hormone resistance in breast cancer by downregulating estrogen receptor-alpha","volume":"31","author":"Vesuna","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/bs.enz.2018.08.004_bb0120","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/ijc.11508","article-title":"DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma","volume":"107","author":"Fackler","year":"2003","journal-title":"Int. J. Cancer"},{"key":"10.1016\/bs.enz.2018.08.004_bb0125","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1128\/MCB.06315-11","article-title":"Twist-1 induces Ezh2 recruitment regulating histone methylation along the Ink4A\/Arf locus in mesenchymal stem cells","volume":"32","author":"Cakouros","year":"2012","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0130","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1245\/ASO.2005.04.010","article-title":"Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer","volume":"12","author":"Martin","year":"2005","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0135","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s10549-011-1684-y","article-title":"Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor-positive early breast cancer patients","volume":"133","author":"van Nes","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/bs.enz.2018.08.004_bb0140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1741-7007-10-73","article-title":"TWIST1 associates with NF-kappaB subunit RELA via carboxyl-terminal WR domain to promote cell autonomous invasion through IL8 production","volume":"10","author":"Li","year":"2012","journal-title":"BMC Biol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0145","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jcb.22651","article-title":"Twist-ing cell fate: mechanistic insights into the role of twist in lineage specification\/differentiation and tumorigenesis","volume":"110","author":"Cakouros","year":"2010","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/bs.enz.2018.08.004_bb0150","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1158\/1078-0432.CCR-08-2372","article-title":"Twist1-mediated adriamycin-induced epithelial-mesenchymal transition relates to multidrug resistance and invasive potential in breast cancer cells","volume":"15","author":"Li","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0155","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1038\/onc.2010.115","article-title":"PKB\/AKT phosphorylation of the transcription factor Twist-1 at Ser42 inhibits p53 activity in response to DNA damage","volume":"29","author":"Vichalkovski","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/bs.enz.2018.08.004_bb0160","doi-asserted-by":"crossref","first-page":"E142","DOI":"10.1111\/j.1464-410X.2010.09810.x","article-title":"Twist1 and Y-box-binding protein-1 promote malignant potential in bladder cancer cells","volume":"108","author":"Shiota","year":"2011","journal-title":"BJU Int."},{"key":"10.1016\/bs.enz.2018.08.004_bb0165","first-page":"67","article-title":"Doxorubicin inhibits differentiation and enhances expression of the helix-loop-helix genes Id and mTwi in mouse osteoblastic cells","volume":"28","author":"Glackin","year":"1992","journal-title":"Biochem. Int."},{"key":"10.1016\/bs.enz.2018.08.004_bb0170","doi-asserted-by":"crossref","first-page":"26699","DOI":"10.1074\/jbc.M102664200","article-title":"Insulin-like growth factor 1 (IGF-1)-induced twist expression is involved in the anti-apoptotic effects of the IGF-1 receptor","volume":"276","author":"Dupont","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2018.08.004_bb0175","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/bjc.2013.774","article-title":"c-FOS suppresses ovarian cancer progression by changing adhesion","volume":"110","author":"Oliveira-Ferrer","year":"2014","journal-title":"Br. J. Cancer"},{"key":"10.1016\/bs.enz.2018.08.004_bb0180","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/cr.2011.144","article-title":"Normal and disease-related biological functions of Twist1 and underlying molecular mechanisms","volume":"22","author":"Qin","year":"2012","journal-title":"Cell Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0185","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.cell.2004.06.006","article-title":"Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis","volume":"117","author":"Yang","year":"2004","journal-title":"Cell"},{"key":"10.1016\/bs.enz.2018.08.004_bb0190","doi-asserted-by":"crossref","first-page":"4549","DOI":"10.1158\/0008-5472.CAN-05-3850","article-title":"Exploring a new twist on tumor metastasis","volume":"66","author":"Yang","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0195","doi-asserted-by":"crossref","first-page":"4435","DOI":"10.7314\/APJCP.2012.13.9.4435","article-title":"Silencing of twist expression by RNA interference suppresses epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer","volume":"13","author":"Wang","year":"2012","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/bs.enz.2018.08.004_bb0200","first-page":"3","article-title":"Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures","volume":"4","author":"Fan","year":"2011","journal-title":"BMC Med. Genet."},{"key":"10.1016\/bs.enz.2018.08.004_bb0205","first-page":"413","article-title":"Reversal of multi-drug resistance in ovarian cancer cell by RNA interference","volume":"41","author":"Lou","year":"2006","journal-title":"Zhonghua Fu Chan Ke Za Zhi"},{"key":"10.1016\/bs.enz.2018.08.004_bb0210","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/onc.2017.311","article-title":"EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer","volume":"37","author":"Yamaguchi","year":"2018","journal-title":"Oncogene"},{"key":"10.1016\/bs.enz.2018.08.004_bb0215","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","article-title":"Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy","volume":"140","author":"Domchek","year":"2016","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11912-016-0515-z","article-title":"What is the place of PARP inhibitors in ovarian cancer treatment?","volume":"18","author":"Liu","year":"2016","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/bs.enz.2018.08.004_bb0225","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 1","key":"10.1016\/bs.enz.2018.08.004_bb0230","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","article-title":"PARP inhibitors in ovarian cancer","volume":"27","author":"Ledermann","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0235","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0140-6736(10)60893-8","article-title":"Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial","volume":"376","author":"Audeh","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/bs.enz.2018.08.004_bb0240","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/carcin\/bgt086","article-title":"A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments","volume":"34","author":"Masui","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/bs.enz.2018.08.004_bb0245","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2001-1326-2-3","article-title":"Mechanisms of chemoresistance in cancer stem cells","volume":"2","author":"Abdullah","year":"2013","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/bs.enz.2018.08.004_bb0250","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/dvdy.21685","article-title":"Integrin-linked kinase regulates E-cadherin expression through PARP-1","volume":"237","author":"McPhee","year":"2008","journal-title":"Dev. Dyn."},{"key":"10.1016\/bs.enz.2018.08.004_bb0255","doi-asserted-by":"crossref","first-page":"15008","DOI":"10.18632\/oncotarget.3634","article-title":"PARP inhibitor ABT-888 affects response of MDA-MB-231 cells to doxorubicin treatment, targeting Snail expression","volume":"6","author":"Mariano","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/bs.enz.2018.08.004_bb0260","doi-asserted-by":"crossref","first-page":"4365","DOI":"10.1038\/onc.2011.153","article-title":"Poly(ADP-ribose)-dependent regulation of Snail1 protein stability","volume":"30","author":"Rodriguez","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/bs.enz.2018.08.004_bb0265","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/nature11333","article-title":"Early-stage epigenetic modification during somatic cell reprogramming by Parp1 and Tet2","volume":"488","author":"Doege","year":"2012","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2018.08.004_bb0270","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1084\/jem.20121044","article-title":"Poly(ADP-ribose) polymerase 1 regulates nuclear reprogramming and promotes iPSC generation without c-Myc","volume":"210","author":"Chiou","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/bs.enz.2018.08.004_bb0275","doi-asserted-by":"crossref","first-page":"3772","DOI":"10.1073\/pnas.1108595109","article-title":"SRY (sex determining region Y)-box2 (Sox2)\/poly ADP-ribose polymerase 1 (Parp1) complexes regulate pluripotency","volume":"109","author":"Lai","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.enz.2018.08.004_bb0280","doi-asserted-by":"crossref","first-page":"15531","DOI":"10.3390\/ijms160715531","article-title":"Poly(ADP-ribose) polymerase 1: cellular pluripotency, reprogramming, and tumorogenesis","volume":"16","author":"Jiang","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.enz.2018.08.004_bb0285","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1158\/1541-7786.MCR-16-0287-T","article-title":"Let-7 status is crucial for PARP1 expression in HER2-overexpressing breast tumors","volume":"15","author":"Wielgos","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0290","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1021\/nn3044066","article-title":"Codelivery of an optimal drug\/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo","volume":"7","author":"Meng","year":"2013","journal-title":"ACS Nano"},{"key":"10.1016\/bs.enz.2018.08.004_bb0295","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2018.08.004_bb0300","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrm1568","article-title":"Assembly and function of RNA silencing complexes","volume":"6","author":"Sontheimer","year":"2005","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0305","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/35078107","article-title":"Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells","volume":"411","author":"Elbashir","year":"2001","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2018.08.004_bb0310","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/35053110","article-title":"Role for a bidentate ribonuclease in the initiation step of RNA interference","volume":"409","author":"Bernstein","year":"2001","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2018.08.004_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0092-8674(04)00293-4","article-title":"Dicers at RISC; the mechanism of RNAi","volume":"117","author":"Tijsterman","year":"2004","journal-title":"Cell"},{"key":"10.1016\/bs.enz.2018.08.004_bb0320","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1126\/science.1102513","article-title":"Argonaute2 is the catalytic engine of mammalian RNAi","volume":"305","author":"Liu","year":"2004","journal-title":"Science"},{"key":"10.1016\/bs.enz.2018.08.004_bb0325","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/aja.2010.167","article-title":"Plasmid-based Stat3 siRNA delivered by hydroxyapatite nanoparticles suppresses mouse prostate tumour growth in vivo","volume":"13","author":"Liang","year":"2011","journal-title":"Asian J. Androl."},{"key":"10.1016\/bs.enz.2018.08.004_bb0330","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/nature08956","article-title":"Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles","volume":"464","author":"Davis","year":"2010","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2018.08.004_bb0335","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.4049\/jimmunol.180.6.3729","article-title":"Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses","volume":"180","author":"Forsbach","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0340","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1089\/oli.2009.0180","article-title":"siRNA and innate immunity","volume":"19","author":"Robbins","year":"2009","journal-title":"Oligonucleotides"},{"key":"10.1016\/bs.enz.2018.08.004_bb0345","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1089\/oli.2008.0164","article-title":"Chemical modification of siRNAs for in vivo use","volume":"18","author":"Behlke","year":"2008","journal-title":"Oligonucleotides"},{"key":"10.1016\/bs.enz.2018.08.004_bb0350","doi-asserted-by":"crossref","first-page":"26017","DOI":"10.1074\/jbc.M109.010835","article-title":"Binding and cleavage specificities of human argonaute2","volume":"284","author":"Lima","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.enz.2018.08.004_bb0355","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1093\/nar\/gkr1301","article-title":"mRNA knockdown by single strand RNA is improved by chemical modifications","volume":"40","author":"Haringsma","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0360","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.nano.2015.05.011","article-title":"Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden","volume":"11","author":"Finlay","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/bs.enz.2018.08.004_bb0365","doi-asserted-by":"crossref","first-page":"97","DOI":"10.2174\/156802612798919141","article-title":"siRNA delivery with lipid-based systems: promises and pitfalls","volume":"12","author":"Foged","year":"2012","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/bs.enz.2018.08.004_bb0370","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/cbdd.12052","article-title":"siRNA delivery: from lipids to cell-penetrating peptides and their mimics","volume":"80","author":"Gooding","year":"2012","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/bs.enz.2018.08.004_bb0375","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-416039-2.00005-7","article-title":"Cell-specific siRNA delivery by peptides and antibodies","volume":"502","author":"Lee","year":"2012","journal-title":"Methods Enzymol."},{"issue":"3","key":"10.1016\/bs.enz.2018.08.004_bb0380","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1039\/b414241a","article-title":"Polycationic dendrimers interact with RNA molecules: polyamine dendrimers inhibit the catalytic activity of Candida ribozymes","author":"Wu","year":"2005","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/bs.enz.2018.08.004_bb0385","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1002\/cmdc.200900076","article-title":"PAMAM dendrimers mediate siRNA delivery to target Hsp27 and produce potent antiproliferative effects on prostate cancer cells","volume":"4","author":"Liu","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/bs.enz.2018.08.004_bb0390","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1038\/mt.2011.207","article-title":"Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice","volume":"19","author":"Zhou","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.enz.2018.08.004_bb0395","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1039\/b711242d","article-title":"Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA\/dendrimer complexes","volume":"5","author":"Shen","year":"2007","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/bs.enz.2018.08.004_bb0400","doi-asserted-by":"crossref","first-page":"7781","DOI":"10.1002\/chem.200903258","article-title":"PAMAM dendrimers for siRNA delivery: computational and experimental insights","volume":"16","author":"Pavan","year":"2010","journal-title":"Chemistry"},{"key":"10.1016\/bs.enz.2018.08.004_bb0405","doi-asserted-by":"crossref","first-page":"630654","DOI":"10.1155\/2013\/630654","article-title":"Dendrimers as carriers for siRNA delivery and gene silencing: a review","volume":"2013","author":"Wu","year":"2013","journal-title":"Sci. World J."},{"key":"10.1016\/bs.enz.2018.08.004_bb0410","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1080\/1061186X.2016.1207649","article-title":"Amphiphilic dendritic nanomicelle-mediated co-delivery of 5-fluorouracil and doxorubicin for enhanced therapeutic efficacy","volume":"25","author":"Han","year":"2017","journal-title":"J. Drug Target."},{"key":"10.1016\/bs.enz.2018.08.004_bb0415","doi-asserted-by":"crossref","first-page":"382745","DOI":"10.1155\/2015\/382745","article-title":"RNA-based TWIST1 inhibition via dendrimer complex to reduce breast cancer cell metastasis","volume":"2015","author":"Finlay","year":"2015","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/bs.enz.2018.08.004_bb0420","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.taap.2010.04.014","article-title":"Reactive oxygen species (ROS) induced cytokine production and cytotoxicity of PAMAM dendrimers in J774A.1 cells","volume":"246","author":"Naha","year":"2010","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0425","doi-asserted-by":"crossref","first-page":"105103","DOI":"10.1088\/0957-4484\/20\/10\/105103","article-title":"The decrease of PAMAM dendrimer-induced cytotoxicity by PEGylation via attenuation of oxidative stress","volume":"20","author":"Wang","year":"2009","journal-title":"Nanotechnology"},{"key":"10.1016\/bs.enz.2018.08.004_bb0430","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1477-3155-11-9","article-title":"Polyamidoamine dendrimer impairs mitochondrial oxidation in brain tissue","volume":"11","author":"Nyitrai","year":"2013","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0435","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.taap.2007.07.009","article-title":"Developmental toxicity of low generation PAMAM dendrimers in zebrafish","volume":"225","author":"Heiden","year":"2007","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0440","doi-asserted-by":"crossref","first-page":"8478","DOI":"10.1002\/anie.201203920","article-title":"An amphiphilic dendrimer for effective delivery of small interfering RNA and gene silencing in vitro and in vivo","volume":"51","author":"Yu","year":"2012","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/bs.enz.2018.08.004_bb0445","doi-asserted-by":"crossref","first-page":"11822","DOI":"10.1002\/anie.201406764","article-title":"Adaptive amphiphilic dendrimer-based nanoassemblies as robust and versatile siRNA delivery systems","volume":"53","author":"Liu","year":"2014","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/bs.enz.2018.08.004_bb0450","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/smll.200700005","article-title":"Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs","volume":"3","author":"Lu","year":"2007","journal-title":"Small"},{"key":"10.1016\/bs.enz.2018.08.004_bb0455","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1002\/smll.200901966","article-title":"Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells","volume":"6","author":"Hom","year":"2010","journal-title":"Small"},{"key":"10.1016\/bs.enz.2018.08.004_bb0460","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7150\/thno.7193","article-title":"Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?","volume":"4","author":"Kobayashi","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/bs.enz.2018.08.004_bb0465","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-60761-609-2_3","article-title":"Enhanced permeability and retention (EPR) effect for anticancer nanomedicine drug targeting","volume":"624","author":"Greish","year":"2010","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/bs.enz.2018.08.004_bb0470","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.gt.3301217","article-title":"Polycation liposomes, a novel nonviral gene transfer system, constructed from cetylated polyethylenimine","volume":"7","author":"Yamazaki","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/bs.enz.2018.08.004_bb0475","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1021\/nn900918w","article-title":"Polyethyleneimine coating enhances the cellular uptake of mesoporous silica nanoparticles and allows safe delivery of siRNA and DNA constructs","volume":"3","author":"Xia","year":"2009","journal-title":"ACS Nano"},{"key":"10.1016\/bs.enz.2018.08.004_bb0480","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.nano.2016.11.010","article-title":"Nanoparticle delivery of siRNA against TWIST to reduce drug resistance and tumor growth in ovarian cancer models","volume":"13","author":"Roberts","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/bs.enz.2018.08.004_bb0485","doi-asserted-by":"crossref","first-page":"3983","DOI":"10.1073\/pnas.0530291100","article-title":"Prospective identification of tumorigenic breast cancer cells","volume":"100","author":"Al-Hajj","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.enz.2018.08.004_bb0490","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1158\/0008-5472.CAN-06-2030","article-title":"Identification of pancreatic cancer stem cells","volume":"67","author":"Li","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/bs.enz.2018.08.004_bb0495","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1038\/onc.2010.111","article-title":"TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2\/214","volume":"29","author":"Yin","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/bs.enz.2018.08.004_bb0500","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.addr.2010.03.008","article-title":"Engineering RNA for targeted siRNA delivery and medical application","volume":"62","author":"Guo","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/bs.enz.2018.08.004_bb0505","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1016\/j.nano.2018.04.008","article-title":"Hyaluronic acid conjugated nanoparticle delivery of siRNA against TWIST reduces tumor burden and enhances sensitivity to cisplatin in ovarian cancer","volume":"14","author":"Shahin","year":"2018","journal-title":"Nanomedicine"}],"container-title":["The Enzymes","Mesoporous Silica-based Nanomaterials and Biomedical Applications, Part B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604718300131?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604718300131?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:09:39Z","timestamp":1761743379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604718300131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018]]},"ISBN":["9780128151112"],"references-count":100,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2018.08.004","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2018]]}}}